The European Union has awarded €6.5 million to support a multi-site randomised controlled trial of psilocybin to ease psychological and existential distress in a variety of progressive illnesses like multiple sclerosis (MS) and chronic obstructive pulmonary disorder (COPD).According to the recipients, this is “the first ever European grant to fund clinical research into psychedelic-assisted…
